Q-omics provides the consensus-scored CCL4L2 profile across patient tissues and cancer cell-line models. CCL4L2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CCL4L2 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, CCL4L2 RNA expression shows 13,468 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where CCL4L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCL4L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCL4L2 survival associations across molecular data types. CCL4L2 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCL4L2 RNA expression–survival associations across cancer types. High CCL4L2 expression shows unfavorable associations in UVM, KIRP, ACC and GBM, but favorable associations in SKCM and LGG. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CCL4L2 RNA expression.
This table summarizes CCL4L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CCL4L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCL4L2 shows lower tumor expression in THCA and higher tumor expression in KIRC, STAD, COAD, BRCA and KIRP. The KIRC box plot shows higher CCL4L2 RNA expression in tumor versus normal tissue (log2 FC = +2.308, t-test p < 0.001).
This table shows molecular features associated with CCL4L2 in patient tissues and cancer cell lines. In patient samples, CCL4L2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCL4L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
